Chinese Covid vaccine appears safe in early trials, induces antibody response


Content Team
Image Credit: Shortpedia

After the successful trials of Moderna and Pfizer coronavirus vaccine candidates, the Chinese coronavirus vaccine has also appeared to be safe in an early-phase randomised clinical trial. The vaccine was successful in generating immunity against the infection in volunteers between 18 to 59 years. The vaccine is "capable of inducing a quick antibody response within four weeks of immunisation by giving two doses," said Fengcai Zhu.